[Nicotine in neuropsychiatric movement disorders].
Nicotine has various effects in the CNS, especially in dopaminergic and cholinergic systems, relevant in pathophysiology of neuropsychiatric movement disorders. Nicotine acutely reduce the symptomatology in Parkinson's disease. In neuroleptic-induced Parkinsonism (NIP) acute nicotine application induces positive changes of symptomatology. Chronic application, however, leads to a greater likelihood of NIP. The results concerning tardive dyskinesia are not consistent, but nicotine tends to exercise a positive influence on basic mechanisms. In the Gilles-de-la-Tourette syndrome nicotine reduces the severity and frequency of the tics given in combination with haloperidol.
Erdmann
R
R
Abteilung Klinische Psychiatrie und Psychotherapie der Medizinischen Hochschule Hannover.
D000328:Adult; D017109:Akathisia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002648:Child; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000503:physiopathology; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage* / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D011954:Receptors, Dopamine; D009538:Nicotine; D006220:Haloperidol